Hypothesis

Aged senescent gut epithelial cells actively shape enterochromaffin (EC) cell serotonin output through SASP-mediated modulation of TPH1 expression, converting a transient repair signal into a chronic dysregulation that drives motility and immune dysfunction.

Mechanistic Basis

1. SASP factors such as IL-6 and TGF-β released by senescent epithelium activate STAT3 and SMAD pathways in neighboring EC cells, which respectively up‑regulate and down‑regulate TPH1 transcription (Senescent cells serve beneficial roles in tissue homeostasis).
2. Early‑life senescence exhibits a regenerative SASP that transiently boosts TPH1 via IL-6/STAT3, enhancing serotonin‑dependent epithelial restitution after injury (Young senescent cells exhibit regenerative programs).
3. Chronic senescence shifts the SASP toward TGF‑β dominance, suppressing TPH1 and reducing luminal 5-HT, while simultaneously increasing EC cell sensitivity to 5-HT2B-mediated autocrine senescence induction (Aging guts accumulate senescent epithelial cells).
4. The microbiome‑derived SCFAs normally stimulate TPH1 via FFAR2, but senescent‑cell‑derived TGF‑β blunts this response, uncoupling microbial cues from serotonin output (Gut microbes elevate colonic 5‑HT).

Predictions & Experimental Design

• Prediction 1: In aged mice, genetic ablation of senescent epithelial cells (using p16-3MR or CAR-T) will cause an acute drop in colonic serotonin levels within 48 h, measurable by HPLC (CAR T‑cell clearance of senescent gut cells).
• Prediction 2: This serotonin dip will be rescued by exogenous SCFA administration only when senescent cells are cleared, indicating restored EC‑cell responsiveness.
• Prediction 3: Pharmacologic blockade of TGF‑β signaling in senescent‑rich gut explants will restore TPH1 expression and serotonin release without removing senescent cells, supporting the SASP‑mediated mechanism.
• Experimental approach: Combine flow‑sorted p16^high epithelial cells with EC‑cell cultures; measure TPH1 mRNA, serotonin secretion, and STAT3/SMAD phosphorylation under conditioned media from young vs. old senescent cells (± IL-6/TGF‑β neutralizing antibodies).

Potential Implications

If validated, this hypothesis reframes senolytics not as blunt clearance tools but as timing‑sensitive interventions that must preserve the early‑repair SASP while preventing the late‑stage TGF‑β shift. It also suggests that combining senolytic treatment with SCFA supplementation or TGF‑β inhibitors could sustain serotonin‑driven gut homeostasis in aging.